canagliflozin
Ligand Summary
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
UNII: 6S49DGR869
PubChem: 24812758
Guide to Pharmacology: 4582
ChEMBL: CHEMBL2048484
DrugCentral: 4758
LyCHI: T8JXNHG58WMV
Target Activities
11 Activities
Items per page:
10
1 – 10 of 11
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
EC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
EC50 | ||||||